Search research articles
Contact Us
Filters
Showing results (11-20 of 130) with videos related to
Page
of 13
Sort By:
Blood
|
March 26, 2016
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P Hughes, David M Ross
Leukemia & Lymphoma
|
July 8, 2008
How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
David M Ross, Timothy P Hughes
Nature Reviews. Clinical Oncology
|
February 8, 2017
Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CML
Timothy P Hughes, David M Ross
Leukemia Research
|
January 20, 2021
Changing of the guard: Leukemia Research 2021
Clive S Zent, David M Ross
Hematology. American Society of Hematology. Education Program
|
December 14, 2011
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?
Junia V Melo, David M Ross
Frontiers in Bioscience (Elite Edition)
|
September 21, 2017
Effects and mechanisms of actions of phytochemicals on Alzheimer's disease neuropathology
Richard E Hartman, David M Ross
Nature Reviews. Clinical Oncology
|
May 8, 2020
Treatment-free remission in patients with chronic myeloid leukaemia
David M Ross, Timothy P Hughes
British Journal of Haematology
|
April 24, 2014
How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia
David M Ross, Timothy P Hughes
Current Oncology (Toronto, Ont.)
|
December 10, 2014
Need to minimize bias when surveying patient attitudes to stopping cml treatment
Lucia A Villemagne-Sanchez, David M Ross, Penelope Schofield
Leukemia & Lymphoma
|
June 20, 2007
Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia
David M Ross, Sharon R Jackson, Peter J Browett
Page
of 13
Search research articles
Search
Showing results (11-20 of 130) with videos related to
Sort By:
Page
of 13
Blood
|
March 26, 2016
Moving treatment-free remission into mainstream clinical practice in CML
Timothy P Hughes, David M Ross
Leukemia & Lymphoma
|
July 8, 2008
How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
David M Ross, Timothy P Hughes
Nature Reviews. Clinical Oncology
|
February 8, 2017
Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CML
Timothy P Hughes, David M Ross
Leukemia Research
|
January 20, 2021
Changing of the guard: Leukemia Research 2021
Clive S Zent, David M Ross
Hematology. American Society of Hematology. Education Program
|
December 14, 2011
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?
Junia V Melo, David M Ross
Frontiers in Bioscience (Elite Edition)
|
September 21, 2017
Effects and mechanisms of actions of phytochemicals on Alzheimer's disease neuropathology
Richard E Hartman, David M Ross
Nature Reviews. Clinical Oncology
|
May 8, 2020
Treatment-free remission in patients with chronic myeloid leukaemia
David M Ross, Timothy P Hughes
British Journal of Haematology
|
April 24, 2014
How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia
David M Ross, Timothy P Hughes
Current Oncology (Toronto, Ont.)
|
December 10, 2014
Need to minimize bias when surveying patient attitudes to stopping cml treatment
Lucia A Villemagne-Sanchez, David M Ross, Penelope Schofield
Leukemia & Lymphoma
|
June 20, 2007
Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia
David M Ross, Sharon R Jackson, Peter J Browett
Page
of 13